Quantcast
Connect with us

Pharma chiefs see coronavirus vaccine by year-end, but challenges ‘daunting’

Published

on

Pharmaceutical company executives said Thursday that one or several COVID-19 vaccines could begin rolling out before 2021, but warned the challenges would be “daunting” as it was estimated that 15 billion doses would be needed to halt the pandemic.

Well over 100 labs around the world are scrambling to come up with a vaccine against the novel coronavirus, including 10 that have made it to the clinical trial stage.

ADVERTISEMENT

“The hope of many people is that we will have a vaccine, hopefully several, by the end of this year,” Pascal Soriot, head of AstraZeneca, told a virtual briefing.

His company is partnering with the University of Oxford to develop and distribute a vaccine being trialled in Britain.

Albert Bourla, head of Pfizer, meanwhile said that his company, which is conducting clinical trials with German firm Biontech on several possible vaccines in Europe and the United States, also believed one would be ready before the end of the year.

“If things go well, and the stars are aligned, we will have enough evidence of safety and efficacy so that we can… have a vaccine around the end of October,” he said.

It can take years for a new vaccine to be licensed for general use, but in the face of the COVID-19 pandemic, experimental vaccines shown to be safe and effective against the novel coronavirus could likely win approval for emergency use.

ADVERTISEMENT

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), which organised Thursday’s briefing, highlighted the “daunting” challenges facing the industry in the push for a vaccine.

– ‘Running against time’ –

One challenge, which may seem counterintuitive, is that transmission rates are rapidly declining in Europe where some of the trials are taking place.

ADVERTISEMENT

Soon they will be too low to properly conduct clinical vaccine trials in a natural setting, Soriot said, adding that so-called “human challenge” studies in which people are intentionally exposed to the virus to test efficacy, were not considered ethically acceptable with COVID-19.

“We are running against time,” he said.

ADVERTISEMENT

The novel coronavirus has killed more than 355,000 people and infected at least 5.7 million worldwide in a matter of months.

IFPMA director Thomas Cueni pointed to estimates that the world will need some 15 billion doses to stop the virus, posing massive logistical challenges.

He stressed that the industry was committed to ensuring equitable access to a future vaccine, but acknowledged that “we will not have sufficient quantities as from day one, even with the best efforts.”

ADVERTISEMENT

Once a working vaccine is developed, one of the biggest obstacles to putting out the amount needed could surprisingly be that there are not enough glass vials to store the doses in.

“There are not enough vials in the world,” Soriot said, adding that AstraZeneca, like a number of other firms, was looking into the possibility of putting multiple doses in each vial.

– IP ‘fundamental’ –

Paul Stoffels, vice chairman and chief scientific officer at Johnson and Johnson, meanwhile said that if 15 billion doses were needed, a number of different vaccines would be necessary to satisfy the initial demand.

ADVERTISEMENT

“Not all vaccine candidates could go all over the world depending on features, so somewhere between five and 10 will definitely be needed to serve the whole world,” he said.

One challenge could be that some of the vaccines being worked on require storage at very low temperatures, which could be difficult in places lacking the proper infrastructure.

While stressing the need for solidarity and for ensuring fair and equitable distribution of a COVID-19 vaccine, the pharmaceutical chiefs flatly rejected any suggestion that intellectual property rights should be waived on vaccine research.

“IP is absolutely fundamental to our industry,” GSK chief Emma Walmsley said.

ADVERTISEMENT

Soriot meanwhile pointed out that pharmaceutical companies are currently investing billions of dollars with little chance of recuperating the costs.

“If you don’t protect IP, then essentially there is no incentive for anybody to innovate,” he said.


Report typos and corrections to: [email protected].
READ COMMENTS - JOIN THE DISCUSSION
Continue Reading

Breaking Banner

‘It’s back-to-back 9/11s’: MSNBC’s Nicolle Wallace blasts Trump’s failed leadership on coronavirus pandemic

Published

on

Speaking to physician Dr. Kavita Patel on Friday, MSNBC's Nicolle Wallace noted that the coronavirus crisis, along with the Russian bounty scandal, the recession and increasing unemployment numbers are like a bunch of little "back-to-back 9/11s."

Wallace, who served in the White House communications department under President George W. Bush saw 9/11 and the aftermath first hand. Under Trump's leadership, there have been several little crises one right after another. While 9/11 killed nearly 3,000 people and nearly that many have died due to injuries and illnesses connected to 9/11, nearly 135,000 Americans have died from COVID-19.

Continue Reading

COVID-19

As coronavirus spikes break new records Dr. Fauci reveals Trump doesn’t even speak to him anymore

Published

on

President Donald Trump tried to claim the mantle of a "wartime president," battling the "unseen enemy," but as it turns out one of the people who could best help him with the coronavirus battle is who's really "unseen."

Dr. Anthony Fauci, an immunologist and probably the most respected public health expert on the government's payroll, reveals the President of the United States no longer talks to him.

In fact, Trump hasn't talked to Fauci, the director of the National Institute of Allergy and Infectious Diseases (NIAID), in over a month – and hasn't been able to update Trump in at least two.

Continue Reading
 

Breaking Banner

Trump campaign headquarters in Virginia shut down for COVID-19 after staffers pressured against wearing face masks

Published

on

President Donald Trump's campaign office, located in northern Virginia just outside of Washington, was forced to shut down after a COVID-19 outbreak.

Politico reported Friday that for a week cleaners were brought into the headquarters to scrub surfaces, disinfect equipment and try and stave off the coronavirus from hitting the campaign more than it already has.

While in Tulsa, Oklahoma, eight members of Trump's advance team contracted the coronavirus, including Secret Service agents. While in Arizona the following week, more of Trump's Secret Service got the virus. To make matters worse, when Trump headed to South Dakota for a Fourth of July celebration, his son's girlfriend, who also works on the campaign, contracted the virus.

Continue Reading
 
 
You need honest news coverage. Help us deliver it. Join Raw Story Investigates for $1. Go ad-free.
close-image